This is a phase II study of an investigational agent, brivanib, in patients with refractory
metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of
brivanib in renal cell carcinoma, and explore the activity of this drug in this population to
determine whether imaging and molecular features of the tumors can be used to predict
response. Approximately 30 people with advanced kidney cancer will be enrolled on this study
at the University of Pennsylvania.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania